Your browser doesn't support javascript.
loading
Clinical outcomes and predictive value of programmed cell death-ligand 1 expression in response to anti-programmed cell death 1/ligand 1 antibodies in non-small cell lung cancer patients with performance status 2 or greater.
Jodai, Takayuki; Saruwatari, Koichi; Ikeda, Tokunori; Moriyama, Eiji; Kashiwabara, Kosuke; Shingu, Naoki; Iyonaga, Kazuhiro; Inaba, Megumi; Ajishi, Yusuke; Honda, Chiharu; Hirosako, Susumu; Maruyama, Hirotaka; Kakiuchi, Yosuke; Eida, Hirofumi; Tomita, Yusuke; Saeki, Sho; Ichiyasu, Hidenori; Sakagami, Takuro.
Afiliación
  • Jodai T; Department of Respiratory Medicine, Kumamoto University Hospital, 1-1-1, Honjo, Chuo-ku, Kumamoto, 860-8556, Japan.
  • Saruwatari K; Department of Respiratory Medicine, Kumamoto University Hospital, 1-1-1, Honjo, Chuo-ku, Kumamoto, 860-8556, Japan. ksaruwat@kuh.kumamoto-u.ac.jp.
  • Ikeda T; Department of Clinical Investigation, Kumamoto University Hospital, Kumamoto, Japan.
  • Moriyama E; Department of Medical Oncology, Miyazaki Higashi Hospital, Miyazaki, Japan.
  • Kashiwabara K; Department of Respiratory Medicine, Kumamoto Regional Medical Center, Kumamoto, Japan.
  • Shingu N; Department of Respiratory Medicine, Saiseikai Kumamoto Hospital, Kumamoto, Japan.
  • Iyonaga K; Department of Respiratory Medicine, Japanese Red Cross Kumamoto Hospital, Kumamoto, Japan.
  • Inaba M; Department of Respiratory Medicine, Kumamoto Chuo Hospital, Kumamoto, Japan.
  • Ajishi Y; Department of Respiratory Medicine, Miyazaki Prefectural Nobeoka Hospital, Nobeoka, Japan.
  • Honda C; Department of Respiratory Medicine, Tamana Central Hospital, Tamana, Japan.
  • Hirosako S; Department of Respiratory Medicine, Omuta Tenryo Hospital, Omuta, Japan.
  • Maruyama H; Department of Respiratory Medicine, Japan Organization of Occupational Health and Safety, Kumamoto Rosai Hospital, Yatushiro, Japan.
  • Kakiuchi Y; Department of Respiratory Medicine, National Hospital Organization Kumamoto Saishun Medical Center, Koshi, Japan.
  • Eida H; Department of Respiratory Medicine, Minamata City General Hospital and Medical Center, Minamata, Japan.
  • Tomita Y; Department of Respiratory Medicine, Kumamoto University Hospital, 1-1-1, Honjo, Chuo-ku, Kumamoto, 860-8556, Japan.
  • Saeki S; Department of Respiratory Medicine, Kumamoto University Hospital, 1-1-1, Honjo, Chuo-ku, Kumamoto, 860-8556, Japan.
  • Ichiyasu H; Department of Respiratory Medicine, Kumamoto University Hospital, 1-1-1, Honjo, Chuo-ku, Kumamoto, 860-8556, Japan.
  • Sakagami T; Department of Respiratory Medicine, Kumamoto University Hospital, 1-1-1, Honjo, Chuo-ku, Kumamoto, 860-8556, Japan.
Int J Clin Oncol ; 26(1): 78-86, 2021 Jan.
Article en En | MEDLINE | ID: mdl-32965577
BACKGROUND: Anti-programmed cell death protein-1/ligand-1 (anti-PD-1/PD-L1) therapy is promising for patients with non-small-cell lung cancer (NSCLC); however, clinical trials have focused on patients with a performance status (PS) 0 or 1. This study aimed to evaluate the clinical outcomes and correlation between PD-L1 expression status and tumor response to anti-PD-1/PD-L1 therapy among NSCLC patients with poor PS (i.e., PS ≥ 2). METHODS: In total, 130 patients with NSCLC and PS ≥ 2 treated with anti-PD-1/PD-L1 monotherapy at 12 institutions between January 2016 and August 2019 were retrospectively reviewed. PD-L1 expression status was divided into four groups: < 1%, 1-49%, ≥ 50%, and unknown. RESULTS: The objective response rate and PS improvement rate were 23 and 21% and were higher in the PD-L1 ≥ 50% group than in other groups (P < 0.01). Median progression-free survival (PFS) was 62 days and was longer in the PD-L1 ≥ 50% group than in other groups (P = 0.03). Multivariate analyses revealed that PD-L1 expression is significantly associated with prolonged PFS (PD-L1 < 1%; reference; 1-49%, hazard ratio [HR] 0.19, 95% confidence interval [CI] 0.04-0.99, P = 0.05; ≥ 50%, HR 0.12, 95% CI 0.02-0.71, P = 0.02; unknown, HR 0.30, 95% CI 0.08-1.22, P = 0.09). CONCLUSIONS: NSCLC patients with poor PS and PD-L1 ≥ 50% are expected to benefit from anti-PD-1/PD-L1 therapy, despite a modest overall response among NSCLC patients with poor PS. Accordingly, PD-L1 expression provides useful information regarding decision-making for anti-PD-1/PD-L1 therapy even in these populations.
Asunto(s)
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Carcinoma de Pulmón de Células no Pequeñas / Antineoplásicos Inmunológicos / Neoplasias Pulmonares Tipo de estudio: Observational_studies / Prognostic_studies / Risk_factors_studies Límite: Humans Idioma: En Revista: Int J Clin Oncol Asunto de la revista: NEOPLASIAS Año: 2021 Tipo del documento: Article País de afiliación: Japón Pais de publicación: Japón
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Carcinoma de Pulmón de Células no Pequeñas / Antineoplásicos Inmunológicos / Neoplasias Pulmonares Tipo de estudio: Observational_studies / Prognostic_studies / Risk_factors_studies Límite: Humans Idioma: En Revista: Int J Clin Oncol Asunto de la revista: NEOPLASIAS Año: 2021 Tipo del documento: Article País de afiliación: Japón Pais de publicación: Japón